Cargando…

Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis

Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the underst...

Descripción completa

Detalles Bibliográficos
Autores principales: Andronis, Christos, Silva, João Pedro, Lekka, Eftychia, Virvilis, Vassilis, Carmo, Helena, Bampali, Konstantina, Ernst, Margot, Hu, Yang, Loryan, Irena, Richard, Jacques, Carvalho, Félix, Savić, Miroslav M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395038/
https://www.ncbi.nlm.nih.gov/pubmed/32504122
http://dx.doi.org/10.1007/s00204-020-02788-1
_version_ 1783565322706485248
author Andronis, Christos
Silva, João Pedro
Lekka, Eftychia
Virvilis, Vassilis
Carmo, Helena
Bampali, Konstantina
Ernst, Margot
Hu, Yang
Loryan, Irena
Richard, Jacques
Carvalho, Félix
Savić, Miroslav M.
author_facet Andronis, Christos
Silva, João Pedro
Lekka, Eftychia
Virvilis, Vassilis
Carmo, Helena
Bampali, Konstantina
Ernst, Margot
Hu, Yang
Loryan, Irena
Richard, Jacques
Carvalho, Félix
Savić, Miroslav M.
author_sort Andronis, Christos
collection PubMed
description Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and elucidate potential biological mechanisms of action frequently associated with MCAEs, we present a unique workflow linking observational population data with the available knowledge at molecular, cellular, and psychopharmacology levels. It is based on statistical analysis of pharmacovigilance reports and subsequent signaling pathway analyses, followed by evidence-based expert manual curation of the outcomes. Our analysis: (a) ranked pharmaceuticals with high occurrence of such adverse events (AEs), based on disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database, and (b) identified 120 associated genes and common pathway nodes possibly underlying MCAEs. Nearly two-thirds of the identified genes were related to immune modulation, which supports the critical involvement of immune cells and their responses in the regulation of the central nervous system function. This finding also means that pharmaceuticals with a negligible central nervous system exposure may induce MCAEs through dysregulation of the peripheral immune system. Knowledge gained through this workflow unravels putative hallmark biological targets and mediators of drug-induced mood and cognitive disorders that need to be further assessed and validated in experimental models. Thereafter, they can be used to substantially improve in silico/in vitro/in vivo tools for predicting these adversities at a preclinical stage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-020-02788-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7395038
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73950382020-08-18 Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis Andronis, Christos Silva, João Pedro Lekka, Eftychia Virvilis, Vassilis Carmo, Helena Bampali, Konstantina Ernst, Margot Hu, Yang Loryan, Irena Richard, Jacques Carvalho, Félix Savić, Miroslav M. Arch Toxicol Organ Toxicity and Mechanisms Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and elucidate potential biological mechanisms of action frequently associated with MCAEs, we present a unique workflow linking observational population data with the available knowledge at molecular, cellular, and psychopharmacology levels. It is based on statistical analysis of pharmacovigilance reports and subsequent signaling pathway analyses, followed by evidence-based expert manual curation of the outcomes. Our analysis: (a) ranked pharmaceuticals with high occurrence of such adverse events (AEs), based on disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database, and (b) identified 120 associated genes and common pathway nodes possibly underlying MCAEs. Nearly two-thirds of the identified genes were related to immune modulation, which supports the critical involvement of immune cells and their responses in the regulation of the central nervous system function. This finding also means that pharmaceuticals with a negligible central nervous system exposure may induce MCAEs through dysregulation of the peripheral immune system. Knowledge gained through this workflow unravels putative hallmark biological targets and mediators of drug-induced mood and cognitive disorders that need to be further assessed and validated in experimental models. Thereafter, they can be used to substantially improve in silico/in vitro/in vivo tools for predicting these adversities at a preclinical stage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-020-02788-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-06-05 2020 /pmc/articles/PMC7395038/ /pubmed/32504122 http://dx.doi.org/10.1007/s00204-020-02788-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Organ Toxicity and Mechanisms
Andronis, Christos
Silva, João Pedro
Lekka, Eftychia
Virvilis, Vassilis
Carmo, Helena
Bampali, Konstantina
Ernst, Margot
Hu, Yang
Loryan, Irena
Richard, Jacques
Carvalho, Félix
Savić, Miroslav M.
Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
title Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
title_full Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
title_fullStr Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
title_full_unstemmed Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
title_short Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
title_sort molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
topic Organ Toxicity and Mechanisms
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395038/
https://www.ncbi.nlm.nih.gov/pubmed/32504122
http://dx.doi.org/10.1007/s00204-020-02788-1
work_keys_str_mv AT andronischristos molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT silvajoaopedro molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT lekkaeftychia molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT virvilisvassilis molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT carmohelena molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT bampalikonstantina molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT ernstmargot molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT huyang molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT loryanirena molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT richardjacques molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT carvalhofelix molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis
AT savicmiroslavm molecularbasisofmoodandcognitiveadverseeventselucidatedviaacombinationofpharmacovigilancedataminingandfunctionalenrichmentanalysis